Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $16.50

Shares of Immuneering Corporation (NASDAQ:IMRX) have received an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $16.50.

Several research firms recently commented on IMRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Immuneering in a research report on Monday, March 9th.

Immuneering Price Performance

Shares of IMRX opened at $4.96 on Monday. Immuneering has a 1 year low of $1.10 and a 1 year high of $10.08. The stock has a 50 day simple moving average of $5.05 and a two-hundred day simple moving average of $6.07. The firm has a market cap of $320.66 million, a P/E ratio of -3.59 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Friday, March 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.13. On average, equities analysts anticipate that Immuneering will post -1.86 earnings per share for the current year.

Insider Transactions at Immuneering

In related news, Director Thomas J. Schall bought 21,645 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was bought at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the acquisition, the director directly owned 74,530 shares of the company’s stock, valued at $348,055.10. The trade was a 40.93% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Peter Feinberg purchased 20,000 shares of Immuneering stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the transaction, the director owned 135,441 shares in the company, valued at $589,168.35. The trade was a 17.32% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 51,819 shares of company stock valued at $234,472. 22.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in shares of Immuneering in the first quarter worth $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Immuneering during the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in Immuneering during the 3rd quarter valued at $35,000. Future Financial Wealth Managment LLC bought a new stake in Immuneering in the 3rd quarter worth $35,000. Finally, Kingsview Wealth Management LLC bought a new stake in Immuneering in the 2nd quarter worth $47,000. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.